misspelledsearch.com:

bextra class action

information page

If you cannot find the information you are searching for on this page, we suggest searching Google with the correct spelling "bextra class action":

Valdecoxib
4-(5-methyl-3-phenyl-4-isoxazolyl)-benzenesulfonamide
CAS number 181695-72-7	ATC code M01AH03
Chemical formula	C16H14N2O3S
Molecular weight	314.364
Bioavailability	83%
Metabolism	10%
Elimination half-life	8-11 hours
Excretion	90%
Pregnancy category	In late pregnancy, valdecoxib should be avoided because it may cause premature closure of the ductus arteriosus.
Legal status	Recalled in US, EU, Canada & parts of Asia
Routes of administration	10mg Oral
Information Source:	FDA Bextra Labeling Information. FDA Bextra Labeling Information. URL accessed on April 8, 2005.

Valdecoxib is a prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should not be taken by anyone allergic to these types of medications.

Valdecoxib was manufactured and marketed under the brand name Bextra® by G. D. Searle & Company. It was available by prescription in tablet form until 2005, when it was removed from the market due to concerns about possible increased risk of heart attack and stroke.

Uses

Since its registration, Bextra was prescribed for pain associated with arthritis, menstrual discomfort, and other ailments.

Side-effects and withdrawal

On April 7, 2005, Pfizer withdrew Bextra from the US market on recommendation by the FDA, citing an increased risk of heart attack and stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx. Other reported side-effects were angina and Stevens-Johnson syndrome.

Pfizer first acknowledged cardiovascular risks associated with Bextra in October of 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos.

Personal injury

With the removal of the drug from the market, there is expected to be a surge in personal injury claims, many in the form of class action, to seek compensation.

External link

• FDA Alert on Bextra withdrawal

This bextra class action index site has been developed to help wayward users find the information they are looking for, no matter how they are mistakenly spelled or mistyped. This site is designed to help users find bextra class action information for the following query variants:

bextra class	bextra class cation	bextra class actiom	bextra class acsion
bextra class acton	bextra class acshun	bextra class acshon	bextra class acchon
bextra class acchun	bextra class catiom	bextra class caton	bextra class cashun
bextra class cashon	bextra class casion	bextra class cachon	bextra class cachun
bextra class atiom	bextra class ation	bextra class achon	bextra class achun
bextra class asion	bextra class aton	bextra class ashun	bextra class ashon
bextra class actin	bextra class acteign	bextra class actiegn	bextra class acten
bextra class actan	bextra class actun	bextra class actlon	bextra class actino
bextra class actoin	bextra class aciton	bextra class atcion	bextra class actio
bextra class acion	bextra class ction	bextra action	bextra crass action
bextra ras action	bextra lass action	bextra rass action	bextra las action
bextra cass action	bextra cas action	bextra clas action	bextra cras action
bextra cias action	bextra clsas action	bextra calss action	bextra lcass action
class action	extra class action	extla class action	bextla class action
bextar class action	bexrta class action	betxra class action	bxetra class action
ebxtra class action	bextr class action	bexta class action	bexra class action
betra class action	bxtra class action

If you would like to add or correct the content of this site, or if you are interested in supporting the efforts of misspelledsearch.com by placing your product information on these bextra class action pages, please contact mistype@gmail.com for details.